SECTION 5: 510(k) SUMMARY

This 510(k) summary is being submitted in accordance with the requirements of the Safe Medical Devices Act of 1990, 21 CFR 807.92

1. General Information
   Date of Submission: March 20, 2012
   Submitted By: Solta Medical, Inc.
   25881 Industrial Blvd
   Hayward, CA 94545
   Contact Person: Kristine Foss
   V.P., Regulatory, Clinical & Quality
   510-780-4657 (Direct Phone)
   510-780-4857 Fax
   kfoss@solta.com

2. Trade/Proprietary Name of Device:
   Trade Name: Clear + Brilliant™ Laser System
   Common Name: Laser Surgical Instrument
   Regulation Number 878.4810
   Product Code: GEX/ONG
   Device Panel: General Surgery/Restorative Devices
   Device Classification: Class II

3. Legally Marketed Predicate Devices for Claimed Equivalence:
   Name: Clear + Brilliant™ Laser System
   510(k) #: K110349
   Name: Fraxel® DUAL 1550/1927 Laser System
   510(k) #: K101490

4. Device Description

   The Clear + Brilliant™ Laser System is a non-ablative laser system designed for use in non-invasive dermatological procedures.
   The Clear + Brilliant Laser System has a laser source in the hand piece which is controlled by an embedded processor. The console is electrically connected to the facility power source. Laser energy produced by the unit is delivered to the tissue through the removable (disposable) contact treatment tips which attach to the hand piece.
The original Clear + Brilliant Laser System has a single hand piece containing a 1440 nm diode laser. A second hand piece with a 1927 nm diode laser has been added to the system as a line extension which provides an additional laser wavelength option at the same low power settings of the predicate Clear + Brilliant Laser System.

5. **Intended Use:**

The Clear + Brilliant Laser System is intended for dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures.

6. **Technological Characteristics:**

The Clear + Brilliant Laser System with an addition of the 1927 nm diode laser is similar to the predicate device in design specification, output energy, and delivery system. They are both laser instruments designed to produce laser energy for soft tissue coagulation and general skin resurfacing during dermatological procedures. The modifications to handpiece hardware, circuitry, and laser wavelength do not significantly affect the safety or effectiveness of the device. The system was evaluated and found compliant with IEC 60601-1 and 60601-1-4 for electrical safety, IEC 60601-1-2 for EMI/EMC, ISO 60825 for laser classification/safety, and 10993-1 for biocompatibility of the treatment tips. Verification and validation data show that the device meets all product specifications.

7. **Performance Data:**

Laboratory and performance tests were executed to ensure that the device functioned as intended and met design specifications. Sufficient data were obtained to show that the device is substantially equivalent to the predicate device and meets safety and effectiveness criteria.

8. **Conclusion:**

By virtue of the design, materials function and intended use, the Clear + Brilliant Laser System is as safe, as effective and performs as well as or better than the predicate device. In establishing substantial equivalence to the predicate device, Solta Medical evaluated the indications for use, product specifications, and energy requirements of the device.
Solta Medical, Inc.
% Ms. Kristine Foss
V.P. Regulatory, Clinical & Quality
25881 Industrial Boulevard
Hayward, California 94545

Re: K120433
Trade/Device Name: Clear - Brilliant™ Laser System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology
Regulatory Class: II
Product Code: ONG
Dated: March 20, 2012
Received: March 22, 2012

Dear Ms. Foss:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safetv/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

Mark N. Melkerson
Director
Division of Surgical, Orthopedic and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): k12043

Device Name: Clear + Brilliant™ Laser System

Indications For Use:

Dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures.

Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]

(Division Sign-Off)
Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number k120433